{
  "docId": "019dd923-622c-750b-8b9a-4b91788fc785",
  "docSlug": "5fadb686cc03",
  "documentTitle": "Twist Bioscience (TWST)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2022-11-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2941177,
  "pageNumber": 190,
  "pageCount": 236,
  "prevPage": 189,
  "nextPage": 191,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a Q&A format to present primary research findings from Scorpion Capital.",
  "elementsJson": [
    "paragraph",
    "quote_block"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-4b91788fc785/190",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-4b91788fc785",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-4b91788fc785.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-4b91788fc785#slide-190",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Customers returning to Genscript after trying Twist suggest its antibody offering is a disaster",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-0933-75bb-9bf4-8becd19b0aaa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "paragraph",
      "text": "We found the Genscript executive’s color regarding Twist’s face-plant in antibody discovery particularly interesting, given that Twist has hyped it as a key growth driver.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64f8315c-c354-4862-b343-457f9bc1c2d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "quote",
      "text": "Yeah, at least 4-5 antibody discovery customers switched to us... They told them they had a plethora of antibodies in their library... but the result that they got didn't present them with that many leads... the timeline... went well over 7-8 months.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "55c98ca3-f483-4117-bb8c-1ef6636f0052",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.05,
        "y": 0.82
      },
      "kind": "quote",
      "text": "To switch over from a tool company to a drug company... it's a bit naïve to think that Twist can hire in Aaron Sato... and think that they're going to do that with all those gigantic legacy manufacturing and overhead.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca33d702-01fa-4c19-be90-d74bc17fb02d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“Yeah, at least 4-5 antibody discovery customers switched to us because that’s the part of the business that I’m in... They pretty much told me the same thing that I described. They told them they had a plethora of antibodies in their library and that they could deliver a certain number of leads based on the screening. But the result that they got didn’t present them with that many leads from the screening. And the timeline that they promised was not kept. It usually takes about 4-5 months, but I think they went well over 7-8 months for many of them. And that actually wasn’t a bad case. For a GMP manufacturing part, it’s like one year.” — Executive at Genscript, key Twist competitor; “To switch over from a tool company to a drug company and make antibodies and things like that, it’s easy to do a couple of deals. It’s hard to actually turn the whole thing around and actually make it into anything...because it’s so different. I’ve been in both worlds. It’s a completely different world. So, I think it’s a bit naïve to think that Twist can hire in Aaron Sato, who’s an antibody expert who did some great things at Sutro and think that they’re going to do that with all those gigantic legacy manufacturing and overhead.” — Longtime executive in Twist’s space",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-0933-75bb-9bf4-8c7c41eb0a61",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.05,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": "source-note",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c371dadf-a284-4cc4-a845-0075a4761ad3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "f5ac97b7-cd54-4091-b63b-4669b596d21b",
      "evidence": "The slide explicitly aims to expose a contradiction between company hype and expert/competitor reality.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}